Stimulant

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.

The Worldwide Narcolepsy Therapeutics Industry is Expected to Reach $5 Billion by 2028 at a 10.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022

The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.

Key Points: 
  • The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
  • Modafinil, armodafinil, and stimulants are only a few of the medications used to treat narcolepsy.
  • Others include sodium oxybate and venlafaxine, which are used to treat the symptoms of sleep paralysis and sleep-related hallucinations (e.g.
  • One of the main factors holding back the narcolepsy market is the high cost of narcolepsy diagnosis and treatment.

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

Retrieved on: 
Friday, September 23, 2022

Eighteen of the enrolled participants have already completed the 8-week treatment in accordance with the study design.

Key Points: 
  • Eighteen of the enrolled participants have already completed the 8-week treatment in accordance with the study design.
  • Part 1 of the Phase II study of ABV-1505 was conducted at UCSF from January 2020 through July 2020 and was accepted by the US Food & Drug Administration in October of 2020.
  • We are also delighted that the University of California, San Francisco is involved in the Phase II Part 2 study.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study

Retrieved on: 
Thursday, April 28, 2022

FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the Phase II, part 2 clinical study of the companys ADHD medicine have completed their site initiation visits (SIV).

Key Points: 
  • FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the Phase II, part 2 clinical study of the companys ADHD medicine have completed their site initiation visits (SIV).
  • We are pleased to complete five site initiation visits (SIV) and initiate patient enrollment for the Phase II Part 2 ADHD clinical trial, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.
  • The UCSF site will complete its IRB approval soon and quickly join study patient enrollment.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Retrieved on: 
Wednesday, February 2, 2022

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.

Key Points: 
  • Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.
  • This randomized, double-blind, placebo-controlled Part 2 study involves a total of approximately 100 patients from the United States and Taiwan.
  • The results from the Part 1 study demonstrated the therapeutic value of PDC-1421 and support further clinical development of ABV-1505 for the treatment of ADHD.
  • We expect to have a productive discussion finalizing the Part 2 study protocol on February 14th, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.

Drug Relieves Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults with ADHD

Retrieved on: 
Tuesday, June 29, 2021

Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.

Key Points: 
  • Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.
  • The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults.
  • "These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD," says Adler.
  • Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function.

Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021

Retrieved on: 
Wednesday, June 9, 2021

The new data analyses showing that FT218 improved excessive daytime sleepiness in patients with narcolepsy, both with and without cataplexy, regardless of stimulant use, are important for this patient population.

Key Points: 
  • The new data analyses showing that FT218 improved excessive daytime sleepiness in patients with narcolepsy, both with and without cataplexy, regardless of stimulant use, are important for this patient population.
  • Moreover, the data demonstrating a reduction in weight is an added benefit for narcolepsy patients, who tend to be overweight.
  • I am encouraged by these and other data and believe FT218, if FDA approved, will be an important once-nightly treatment option for people who struggle with managing narcolepsy.
  • A greater percentage of NT2 patients receiving FT218 were rated as much/very much improved at all three doses vs. placebo.

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

Retrieved on: 
Monday, May 24, 2021

Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.

Key Points: 
  • Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.
  • Supernus has developed a robust patient access program to support those who qualify for treatment.
  • As a non-controlled substance that has a unique profile of proven efficacy, safety, and tolerability, Qelbree provides patients living with ADHD a novel treatment option like no other ADHD medication.
  • Qelbree may increase suicidal thoughts and actions in some children with ADHD, especially within the first few months of treatment or when the dose is changed.

Koios Beverage Corp.: Fit Soda™ to be Carried in Over 100 Southwestern U.S. Locations of a National Convenience Chain with Over 3,800 Stores, Starting in June 2021

Retrieved on: 
Thursday, May 20, 2021

Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.

Key Points: 
  • Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.
  • Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.
  • Koios products have been shown to enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.
  • As each individual is different, the benefits, if any, of taking the Company\xe2\x80\x99s products will vary from person to person.

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Retrieved on: 
Tuesday, May 4, 2021

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.